Clinical data | |
---|---|
Trade names | Suprax, others[1] |
AHFS/Drugs.com | Monograph |
MedlinePlus | a690007 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 30 to 50%[5] |
Protein binding | Approximately 60% |
Elimination half-life | Variable Average 3 to 4 hours |
Excretion | Kidney and biliary |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.119.331 |
Chemical and physical data | |
Formula | C16H15N5O7S2 |
Molar mass | 453.44 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Cefixime, sold under the brand name Suprax among others, is an antibiotic medication used to treat a number of bacterial infections.[5] These infections include otitis media, strep throat, pneumonia, urinary tract infections, gonorrhea, and Lyme disease.[5] For gonorrhea typically only one dose is required.[6] In the United States it is a second-line treatment to ceftriaxone for gonorrhea.[5] It is taken by mouth.[5]
Common side effects include diarrhea, abdominal pain, and nausea.[5] Serious side effects may include allergic reactions and Clostridioides difficile diarrhea.[5] It is not recommended in people with a history of a severe penicillin allergy.[6] It appears to be relatively safe during pregnancy.[7] It is in the third-generation cephalosporin class of medications.[5] It works by disrupting the bacteria's cell wall resulting in its death.[5]
Cefixime was patented in 1979 and approved for medical use in the United States in 1989.[5][8] It is on the World Health Organization's List of Essential Medicines.[9] It is available as a generic medication in the United States.[10]
genericnames
was invoked but never defined (see the help page).